Podcasts
Listen to the latest hemonc news from international experts
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more
This podcast highlights key non-Hodgkin lymphoma (NHL) updates from ASH 2025 across follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. John Burke, MD, Rocky Mountain Cancer Centers, Denver, CO, presents the MorningSun study (NCT05207670) of subcutaneous mosunetuzumab in previously untreated FL, while Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the MITHIC-FL2 trial (NCT05389293) of mosunetuzumab plus zanubrutinib in newly diagnosed FL, followed by results from EPCORE FL-1 (NCT05409066) comparing epcoritamab plus R2 versus R2 alone in relapsed or refractory disease.
In DLBCL, Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, reviews the Phase III OLYMPIA-3 trial (NCT06091865), Jason Westin, MD, MD Anderson Cancer Center, Houston, TX, discusses the Smart Stop study (NCT04978584), and Umberto Vitolo, MD, University of Turin, Italy, with Lorenzo Falchi, covers fixed-duration epcoritamab from the EPCORE DLBCL-3 (NCT05660967) and EPCORE NHL-2 (NCT04663347) trials. Saurabh Dahiya, MD, shares early CAR T-cell data with KITE-753 and KITE-363, Michael Wang, MD, presents Phase I/II sonrotoclax results in MCL (NCT05471843), and Nirav Shah, MD, reviews Phase Ia/b bexobrutideg data in Waldenström’s macroglobulinemia (NCT05131022).
Date: 16th January 2026
